Stroke · patients with coronary heart disease
Antibiotics showed no clear difference in stroke at 24±6 months compared with placebo or no intervention (high certainty).
2 findings from 1 review
Sudden cardiac death · patients with coronary heart disease
Antibiotics probably leads to higher sudden cardiac death at 24±6 months compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
Serious adverse events maximum · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at maximum · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 24±6 months · patients with coronary heart disease
Antibiotics leads to higher all‐cause mortality at 24±6 months compared with placebo or no intervention (high certainty).
1 finding from 1 review
Serious adverse event at 24±6 months · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of pyelonephritis · patients with asymptomatic bacteriuria during pregnancy
Antibiotics may leads to lower development of pyelonephritis compared with no treatment (low certainty).
1 finding from 1 review
Preterm birth · patients with asymptomatic bacteriuria during pregnancy
Antibiotics may leads to lower preterm birth < 37 weeks compared with no treatment (low certainty).
1 finding from 1 review
Low birthweight · patients with asymptomatic bacteriuria during pregnancy
Antibiotics may leads to lower birthweight < 2500 g compared with no treatment (low certainty).
1 finding from 1 review
ICU/HDU admission ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
Symptom score at 10 days. Measured on a 7‐point scale (0 to 6) ; lower score denotes fewer symptoms · acute asthma exacerbation
1 finding from 1 review
All adverse events · acute asthma exacerbation
Antibiotics showed no clear difference in all adverse events compared with placebo or usual care (low certainty).
1 finding from 1 review
Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
1 finding from 1 review
Mortality ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
Length of hospital stay · acute asthma exacerbation
1 finding from 1 review
Relapse ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
PEFR (GIV) Duration 10 days · acute asthma exacerbation
1 finding from 1 review
Children not cured or substantially improved at · prolonged wet cough in children
Antibiotics probably leads to lower children not cured or substantially improved at compared with placebo (moderate certainty).
1 finding from 1 review
Children with progression of the disease resulting in additional medical therapy (complications) (measured as proportion of participants) · prolonged wet cough in children
Antibiotics probably leads to lower children with progression of the disease resulting in additional… compared with placebo (moderate certainty).
1 finding from 1 review
Cure in adults with clinically diagnosed acute rhinosinusitis · acute rhinosinusitis in adults, whether clinically diagnosed or confirmed by imaging
Antibiotics leads to higher cure in adults with clinically diagnosed acute rhinosinusitis compared with placebo (high certainty).
1 finding from 1 review